Alcohol Use Disorder Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight

(Albany, USA) DelveInsight's, "Alcohol Use Disorder Pipeline Insight, 2024" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Alcohol Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

"Alcohol Use Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use Disorder Market.
The Alcohol Use Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Explore our latest breakthroughs in Alcohol Use Disorder Research. Learn more about our innovative pipeline today! @ Alcohol Use Disorder Pipeline Outlook- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Alcohol Use Disorder Pipeline Report
• In November 2024:- Tempero Bio Inc.- The purpose of this study is to assess the safety, tolerability and effect on alcohol use (number of heavy drinking days) of TMP-301 compared to placebo in patients with alcohol use disorder. This is a placebo-controlled, parallel-group, multicenter clinical study in moderate to severe alcohol use disorder with ≥8 heavy drinking days over the prior 4 weeks at screening. Study participants and investigators will be blinded to study intervention. The study duration will be up to 19 weeks, with a treatment duration of up to 14 weeks. The visit frequency will be weekly.
• In November 2024:- Novo Nordisk A/S- The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
• DelveInsight's Alcohol Use Disorder pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Alcohol Use Disorder treatment.
• The leading Alcohol Use Disorder Companies such as Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.
• Promising Alcohol Use Disorder Therapies such as Sunobinop, Psilocybin, CMND-100, TMP-301, Brexanolone, and others.

Stay informed about the cutting-edge advancements in Alcohol Use Disorder treatments. Download for updates and be a part of the revolution in care @ Alcohol Use Disorder Clinical Trials Assessment- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alcohol Use Disorder Emerging Drugs Profile
• AD04: Adial Pharmaceuticals
AD04, developed by Adial Pharmaceuticals, is a genetically targeted therapeutic agent designed to treat Alcohol Use Disorder (AUD). It works by modulating specific neurotransmitter pathways that are implicated in the brain's reward and reinforcement circuits related to alcohol consumption. The drug is being developed for patients with particular genetic markers, identified through a proprietary companion diagnostic genetic test, and has shown promise in reducing heavy drinking days in a subgroup of patients during a Phase III clinical trial. AD04's mechanism of action is believed to involve balancing the activity of the serotonergic and dopaminergic systems, potentially reducing alcohol cravings and consumption.

• MN-166 (ibudilast): MediciNova
MN-166 (ibudilast) portfolio, which includes the phase II-staged lead drug compound and proprietary analogs, represents novel, first-in-class, non-opioid drugs for the treatment of drug addiction, progressive multiple sclerosis and pain. MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6, and upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. Ibudilast's anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease), substance abuse/addiction and chronic neuropathic

• BICX104: BiocorRx Pharmaceuticals
BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder (OUD) being developed to improve patient compliance to naltrexone therapy compared to other marketed treatments. In Phase I, an open-label, single-center study in two parallel groups of randomized healthy volunteers to evaluate the PK and safety of BICX104 and the once-a-month intramuscular naltrexone injection (Vivitrol), BICX104 was well tolerated with no serious adverse events and achieved 84 days of therapeutic naltrexone plasma concentrations. BICX104 is being developed under BioCorRx Pharmaceuticals Inc., the Company's majority-owned clinical-stage pharmaceutical subsidiary. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Alcohol Use Disorder.

Learn more about Alcohol Use Disorder Drugs opportunities in our groundbreaking Alcohol Use Disorder Research and development projects @ Alcohol Use Disorder Unmet Needs- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alcohol Use Disorder Companies
Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.

Alcohol Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Alcohol Use Disorder Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Alcohol Use Disorder treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Alcohol Use Disorder Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Alcohol Use Disorder Pipeline Report
• Coverage- Global
• Alcohol Use Disorder Companies- Cybin, Indivio, BioXcel Therapeutics, BiocorRx Pharmaceuticals, Beckley Psytech, MediciNova, Adial Pharmaceuticals, and others.
• Alcohol Use Disorder Therapies- Sunobinop, Psilocybin, CMND-100, TMP-301, Brexanolone, and others.
• Alcohol Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Alcohol Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Alcohol Use Disorder Pipeline on our website @ Alcohol Use Disorder Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/alcohol-use-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Alcohol Use Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Alcohol Use Disorder- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AD04: Adial Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MN-166 (ibudilast): MediciNova
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BICX104: BiocorRx Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Alcohol Use Disorder Key Companies
21. Alcohol Use Disorder Key Products
22. Alcohol Use Disorder- Unmet Needs
23. Alcohol Use Disorder- Market Drivers and Barriers
24. Alcohol Use Disorder- Future Perspectives and Conclusion
25. Alcohol Use Disorder Analyst Views
26. Alcohol Use Disorder Key Companies
27. Appendix

Trending Report:
• Molecular Glue Trials: https://www.delveinsight.com/report-store/molecular-glues-competitive-landscape
• Cellulitis Market: https://www.delveinsight.com/blog/acute-bacterial-skin-and-skin-structure-infection-and-current-therapeutic-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Graft Versus Host Disease Market: https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-epidemiology-forecast
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Xerostomia Market: https://www.delveinsight.com/whitepaper-newsletter/xerostomia-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/infographics/bronchopulmonary-dysplasia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Head And Neck Squamous Cell Carcinoma Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Thrombocytopenia Market: https://www.delveinsight.com/report-store/thrombocytopenia-market
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Benefits Of Robotics In Healthcare: https://www.delveinsight.com/blog/robotics-in-healthcare
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Acute Ocular Pain And Inflammation Market: https://www.delveinsight.com/report-store/acute-ocular-pain-aop-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Anal Cancer Market: https://www.delveinsight.com/report-store/anal-cancer-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.